GlaxoSmithKline vaccine receives EU backing

GlaxoSmithKline’s Synflorix vaccine has received positive opinion, the company has announced.

The jab – used as an immunisation against invasive pneumococcal disease in young children – was given the backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use, with marketing authorisation expected to be granted later this year.

Commenting on the endorsement, Jean Stephenne, president and general manager of the company’s biologicals subsidiary, stated the injection has the potential of a “significant public health benefit”, both on the continent and further afield.

He added: “Once approved, this important paediatric vaccine, which fits easily into existing vaccination schedules, will provide doctors with a new option in preventing life threatening pneumococcal disease and middle ear infections.”

Along with Europe, the ten-valeant pneumococcal conjugate jab has been tested in Africa, Asia and Latin America.

Last month, GlaxoSmithKline announced its product Duodart had been filed for European Marketing Authorisation.

The drug is used as a treatment for men who suffer from moderate to severe symptoms of benign prostatic hyperplasia.